Bicycle Therapeutics (NASDAQ:BCYC) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Bicycle Therapeutics (NASDAQ:BCYC) released its quarterly earnings data on Tuesday. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.10, Briefing.com reports. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm’s revenue was down 30.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.16) earnings per share.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $11.32 on Thursday. The company has a 50-day simple moving average of $13.35 and a 200 day simple moving average of $19.46. The company has a market capitalization of $781.65 million, a price-to-earnings ratio of -3.44 and a beta of 0.93. Bicycle Therapeutics has a 52 week low of $10.91 and a 52 week high of $28.67.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, insider Santiago Arroyo sold 4,943 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $69,646.87. Following the transaction, the insider now owns 69,057 shares in the company, valued at $973,013.13. This represents a 6.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Travis Alvin Thompson sold 2,686 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the sale, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at approximately $482,190. This represents a 7.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,677 shares of company stock worth $392,413 over the last quarter. Company insiders own 8.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. JMP Securities reduced their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday. Stephens reissued an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $29.14.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.